HighVista Strategies’s Harvard Bioscience HBIO Stock Holding History

HighVista Strategies’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,170	Closed	-$66K	–	87
2019 Q4	$66K	Hold	2,170	–	–	0.05%	112
2019 Q3	$67K	Buy	+2,170	New	+$53.9K	0.05%	100

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighVista Strategies's HBIO Position: Q1 2020 in Review

HighVista Strategies sold out of Harvard Bioscience (HBIO) in Q1 2020, closing a stake of 2,170 shares — an estimated $66K sold.

HighVista Strategies first reported a position in HBIO in Q3 2019 and held it in 2 quarters. The position peaked at $67K in Q3 2019. 64 funds tracked by Wall St. Rank hold HBIO as of Q1 2020.

HighVista Strategies reported no remaining Harvard Bioscience position as of Q1 2020 after selling out during the quarter.
HighVista Strategies sold 2,170 Harvard Bioscience shares in Q1 2020, an estimated $66K.
HighVista Strategies first reported a position in Harvard Bioscience in Q3 2019 and held it in 2 quarters.
HighVista Strategies's Harvard Bioscience position peaked at $67K in Q3 2019.
64 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2020.

Based on HighVista Strategies's 13F filing for Q1 2020, filed 15 May 2020.